Novavax Stock News

Novavax, Inc. (NASDAQ:NVAX ) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Execu

Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Televi

The pharmaceutical company saw measurable but modest growth last quarter, but remains in the red. Its vaccine science, however, has motivated a rival drugmaker to enter into a lucrative partnership.

Novavax (NASDAQ: NVAX ) stock investors are celebrating on Friday as the vaccine company's shares hit a new 52-week high after announcing a deal with Sanofi (NASDAQ: SNY ). This saw shares of NVAX s

Novavax (NASDAQ: NVAX ) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi (NASD

Novavax, Inc. (NASDAQ:NVAX) shares surged Friday following the announcement of a significant licensing agreement with Sanofi SA (ADR) (NYSE:SNY), valued at $1.2 billion. The deal encompasses the comme

Novavax (NVAX) signed a deal with drugmaker Sanofi to co-commercialize the Covid Vaccine. Diane King Hall discusses this, as well as Novavax's 1Q earnings.

Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brie

Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to license its vaccine technology to French drugmaker Sanofi (SNY).

Novavax Inc (NASDAQ:NVAX) stock is up 130% to trade at $10.82 today, by far the best stock on the Nasdaq this morning.

Shares for Novavax swelled by more than 140% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for

Novavax (NVAX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $3.41 per share a year ago.

The two companies will also work on a shot that combines Covid-19 and flu vaccines.

Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal wi

Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influen